AstraZeneca Q3 Profit Rises to $3.12 Billion, Reaffirms FY26 Guidance; Shares Climb Premarket

AstraZeneca PLC (AZN) reported third-quarter profit attributable to owners of $3.12 billion, up from $2.53 billion a year earlier, with diluted earnings per share of $2.00 versus $1.62. The company reaffirmed its full-year 2026 guidance and disclosed 12 positive Phase 3 readouts year to date. Total revenue rose 7% at constant exchange rates to $16.21 billion from $15.19 billion for the quarter ended September 30, 2026. Core EPS increased 17% to $2.79, or 19% at CER. For FY26, AstraZeneca expects revenue growth of a mid-to-high single-digit percentage from $58.74 billion in 2025 and low double-digit core EPS growth from $9.16. The company launched a multi-year restructuring program targeting up to $2 billion in one-time costs and $1.5 billion in annualized pre-tax savings by the end of 2029. It also completed a $2 billion equity investment in Summit Therapeutics for roughly 12% of the company. AstraZeneca discontinued the Phase 3 eVOLVE-Lung02 and AWAKE trials after unlikely primary endpoint outcomes. The stock closed Thursday at $174.40, up 2.88%, and traded at $182.18 premarket, up 4.40%.